This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In what is a rarity nowadays for a Southern California venturecapital fund, San Diego- and Cambridge-based venturecapital firm AvalonVentures has just closed on $201.6M in commitments for a $250M fund, AvalonVentures X. The funding was disclosed via a regulatory filing Thursday.
AvalonVentures , the La Jolla- and Cambridge-based venturecapital firm, has backed a new startup, Pingup , which lets consumers text nightclubs for reservations and information. According to Pingup Tuesday, it raised $1M in a seed funding round from AvalonVentures, led by Brady Bohrmann.
The latest venturecapital totals from the PricewaterhouseCoopers/National VentureCapital Association''s MoneyTree Report was released this evening, tallying up $761.12M in investments in Q2 of 2014 in Southern California, up from Q2 of 2013, when $616.83M was invested in the region.
San Diego-based venturecapital investor AvalonVentures and biopharmaceuticals firm GlaxoSmithKline said Monday that the two have teamed up to fund and launch up to 10, early stage life science companies. According to AvalonVentures and GSK, they will provide up to $495M to fund those ten new companies.
San Diego-based AvalonVentures , and COI Pharmaceuticals , the company established by Avalon to help form new biotech companies, said today that the first two companies that it has formed with GlaxoSmithKline have met their first milestones, and that it has spun up a new company with GSK as part of their collaboration.
San Diego-based AvalonVentures said this morning that it has launched and funded three, new companies as part of its deal with GSK. AvalonVenturs said that Adrenergics , CadheRx Therapeutics , and Calporta Therapeutics have all received $10M in Series A funding, and will receive R&D support from AvalonVentures and GSK.
Investments by venture capitalists in Southern California were up, both in terms of deals and dollars in Q2, according to the latest numbers from PricewaterhouseCoopers and the National VentureCapital Association (NVCA). in 91 investments, up significantly from the $451.8M Nationally, venture deals in the U.S.
In the latest positive move for the Los Angeles venturecapital market, a new investor has moved into town, to take advantage of the area''s growing startup market. core innovation capitalventure investment fund' READ MORE>>.
The latest numbers from the PricewaterhouseCoopers/National Venturecapital Association MoneyTree survey, which is based on data from Thomson Reuters, tallies $738.34M invested in Southern California in Q4 of 2011. The amount is up from $528.0M raised in Q4 of 2010, and up from the $652M invested in the region last quarter.
The startup--led by technology startup vet Derrick Oien--said the funding was led by Sinclair Digital Ventures, a division of Sinclair Broadcast Group. Also participating in the funding was AvalonVentures, New Enterprise Associates, and angels, including Kevin Plank (Under Armour) and Paul Palmieri (Millennial Media).
San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday.
The funding was led by AvalonVentures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.
GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venturecapital firm AvalonVentures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.
We caught up with serial entrepreneur Derrick Oien , who is CEO of the company, to learn more. Tell us a little bit about this new startup? Derrick Oien: We started ScoreStream three years ago. It's actually nice that there is a shortage of capital for sports startups. I was at MP3.com, com, and then Intercasting.
We caught up with serial entrepreneur Derrick Oien , who is CEO of the company, to learn more. Tell us a little bit about this new startup? Derrick Oien: We started Sportstream three years ago. It's actually nice that there is a shortage of capital for sports startups. I was at MP3.com, com, and then Intercasting.
ScoreStream, a five-year-old startup that created a social media platform for crowd-sourcing local sports scores, has raised $3.7 million in a Series A round that includes Intel Capital as an investor.
It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s AvalonVentures. Inbio Ventures, a venturecapital management company, represented Pharmstandard in the deal.
First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We are definitely interested in oncology, but there is no value in disclosing details.”.
Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. They can’t be made efficiently and at low cost.”.
After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.
Xconomy is convening life sciences and technology founders, executives, investors, and entrepreneurs for an afternoon of fireside chats and solo talks at Human Impact of Innovation.
Larry’s diagnosis was cancer with a big C: “I have stage 4 pancreatic cancer and have been on chemo since June with some ups and downs,” he wrote in mid-March. After completing his MBA in 1985, Bock joined a now-defunct venture firm in Costa Mesa, CA. Bock started or funded 50 companies; a definitive list is here.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content